Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor
Copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2001
To the Editor: In a study of the effectiveness of a mass immunization campaign in Quebec against meningococcal disease, De Wals et al1 recently reported on a lack of clinical protection against invasive meningococcal type C infections in children younger than 2 years who were immunized with the polysaccharide meningococcal vaccine. Because of concerns about the efficacy of the vaccine in children younger than 2 years, we evaluated the immunogenicity of this vaccine in children younger than 2 years during the same immunization campaign.
Lebel MH, Tapiero BF, Saintonge F. Immunogenicity of Bivalent AC Polysaccharide Meningococcal Vaccine in Children Aged 6 Through 24 Months. JAMA. 2001;285(12):1578-1579. doi:10.1001/jama.285.12.1578